Moorfields Eye Hospital NHS Foundation Trust
Moorfields Eye Hospital NHS Foundation Trust
London, United Kingdom10 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Extension Study for the Port Delivery System With Ranibizumab (Portal) | Neovascular Age-Related Macular Degeneration | Recruiting | Phase 3 | 2026-09-28 | NCT03683251 | |
| A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD | Neovascular Age-related Macular Degeneration | Recruiting | Phase 3 | 2026-09-21 | NCT06847542 | |
| A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration | Neovascular Age-related Macular Degeneration (nAMD) | Active, not recruiting | Phase 4 | 2026-07-31 | NCT06795048 | |
| A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Uveal Neoplasms, eye disorder, malignant choroid melanoma, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, ocular cancer, primitive neuroectodermal tumor, uveal disorder, uveal melanoma | Active, not recruiting | Phase 3 | 2026-07-31 | NCT06007690 | |
| A Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome) | Neovascular Age-related Macular Degeneration (nAMD) | Active, not recruiting | Phase 3 | 2026-07-31 | NCT04657289 | |
| Early Prediction of Outcomes Following Optic Neuritis: Development and Acceptability of a Prognostic Tool | CNS demyelinating autoimmune disease, Disease Attributes, Genetic Risk Score, Hemic and Lymphatic Diseases, Hypersensitivity, Delayed, Pathologic Processes, Pathological Conditions, Signs and Symptoms, acute transverse myelitis, autoimmune disease, autoimmune disorder of the nervous system, cranial nerve neuropathy, demyelinating disease, disease susceptibility, eye disorder, immune system disorder, inherited disease susceptibility, lymphatic system disorder, lymphoproliferative syndrome, multiple sclerosis, nervous system disorder, neuromyelitis optica, optic nerve disorder, optic neuritis, sarcoidosis | Not yet recruiting | Not stated | 2026-07-15 | NCT07704294 | |
| Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION) | Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Eye Abnormalities, Eye Diseases, Hereditary, Leber congenital amaurosis, Leber congenital amaurosis 10, Leber hereditary optic neuropathy, Meckel syndrome, type 4, Neurologic Manifestations, Nutritional and Metabolic Diseases, Pathological Conditions, Signs and Symptoms, Sensation Disorders, Signs and Symptoms, blindness (disorder), cranial nerve neuropathy, eye disorder, hereditary disease, hereditary optic atrophy, inborn mitochondrial metabolism disorder, inherited neurodegenerative disorder, metabolic disease, nervous system disorder, neurodegenerative disease, optic atrophy, optic nerve disorder, retinal disorder, vision disorder | Recruiting | Phase 3 | 2026-06-25 | NCT06891443 | |
| Investigating Epstein-Barr Virus Associated Conjunctivitis | Conjunctival Diseases, DNA Virus Infections, Epstein-Barr virus infection, Herpesviridae infectious disease, Infections, Tumor Virus Infections, conjunctivitis, eye disorder, viral infectious disease | Enrolling by invitation | Not stated | 2024-11-14 | NCT06689397 | |
| UNICORNS: Uveitis in Childhood Prospective National Cohort Study | eye disorder, uveal disorder, uveitis | Active, not recruiting | Not stated | 2024-10-04 | NCT05385757 | |
| Nicotinamide in Glaucoma (NAMinG): A Randomised, Placebo-controlled, Multi-centre, Phase III Trial | eye disorder, glaucoma, ocular hypertension, open-angle glaucoma | Recruiting | Phase 3 | 2024-05-09 | NCT05405868 |